NY-SAR-35 is involved in apoptosis, cell migration, invasion and epithelial to mesenchymal transition in glioma

作者：Wu, Guangyong; Wang, Wei; Liu, Yu; Zhuang, Kai; Cai, Tao; Wang, Zhi Fei; Yang, Liang^*

来源：Biomedicine & Pharmacotherapy, 2018, 97: 1632-1638.

DOI：10.1016/j.biopha.2017.11.076

• Cancer/testis antigen
• NY-SAR-35
• Glioma

Glioma is one of the most adult intracranial tumors worldwide. Cancer testis antigens have been confirmed as new tool for immunotherapy and prognostic biomarkers in a variety of neoplasms. NY-SAR-35 has emerged to be upregulated in diverse human carcinomas. In this study, we aimed to investigate the role of NY-SAR-35 of clinical significance in glioma and investigate whether NY-SAR-35 correlate with malignant behaviors of glioma cells, including cell proliferation, apoptosis, migration, invasion and epithelial-to-mesenchymal transition (EMT). As the results showed, NY-SAR-35 was significantly upregulated in glioma clinical samples and cell lines, and the high expression was significantly associate with age (p = 0.05), the WHO classification (p = 0.02) and KPS score (p = 0.016). Therefore, NY-SAR-35 could serve as an independent prognostic biomarker of glioma patients. Moreover, increased NY-SAR-35 expression remarkably accelerated tumor cells proliferation, restrained cells apoptosis, promoted cells metastasis and contributed to the formation of EMT phenotype. Likewise, down-regulated NY-SAR-35 could obviously inhibit cells proliferation, promote cells apoptosis, supressed metastasis and reverse EMT to MET. In summary, our findings showed that NY-SAR-35 serves as a novel prognostic biomarker and therapeutic target for glioma.

• 出版日期2018-1
• 单位中南大学